BioAtla Inc - Company Profile
Powered by
All the data and insights you need on BioAtla Inc in one report.
- Save hours of research time and resources with
our up-to-date BioAtla Inc Strategy Report
- Understand BioAtla Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioAtla Inc (BioAtla) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate (ADC) that targets AXL, which is a protein kinase receptor. Its BA3021 is developing a CAB antibody-drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. BioAtla is headquartered in San Diego, California, the US.
BioAtla Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Antibody Drug Conjugates (ADC's) | Bioatla |
Monoclonal Antibodies (MAB's) | Conditionally Active Biologics (CAB) |
Pipeline: | Comprehensive Integrated Antibody Optimization |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In May, the company received approval from the U.S. Food and Drug Administration for its new drug application to evaluate BA3361 (CAB-Nectin-4) antibody-drug conjugate for the treatment of multiple tumor types. |
2023 | Regulatory Approval | In February, the company announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to evaluate BA3182 for the treatment of advanced adenocarcinoma. |
2022 | Contracts/Agreements | In January, the company entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo. |
Competitor Comparison
Key Parameters | BioAtla Inc | CytomX Therapeutics Inc | Chinook Therapeutics Inc | CerFlux Inc | Cogent Biosciences Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | San Diego | South San Francisco | Seattle | Birmingham | Waltham |
State/Province | California | California | Washington | Alabama | Massachusetts |
No. of Employees | 65 | 120 | 214 | - | 164 |
Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Jay M. Short | Chairman; Chief Executive Officer | Executive Board | 2020 | 65 |
William Boyle | Director | Executive Board | 2021 | 67 |
Richard A. Waldron | Chief Financial Officer | Senior Management | 2013 | 69 |
Eric L. Sievers | Chief Medical Officer | Senior Management | 2019 | 59 |
Cathy Chang | Senior Vice President - Research and Development | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer